Literature DB >> 10428185

Low prevalence of smoking among patients with obsessive-compulsive disorder.

S Bejerot1, M Humble.   

Abstract

Tobacco smoking is common among psychiatric patients, especially among those with schizophrenia, where the prevalence is extremely high, 74% to 88%, compared with 45% to 70% in patients with other psychiatric diagnoses. Patients with anxiety disorders are less well investigated in this respect, particularly obsessive-compulsive disorder (OCD) patients. Eighty-three psychiatric outpatients with OCD and 110 members of the Swedish OCD Association responded to questions concerning their smoking habits. Among OCD patients, 14% were current smokers (compared with 25% in the general population of Sweden), 72% had never smoked, and 11 previous smokers had stopped, mostly without any difficulties. Since a decreased smoking rate among OCD subjects was confirmed, the smoking prevalences in schizophrenia and OCD, respectively, seem to represent either end of a continuum, and OCD may also differ significantly from other anxiety disorders in this respect. Possible implications of this finding for the purported frontal lobe dysregulation in OCD are discussed.

Entities:  

Mesh:

Year:  1999        PMID: 10428185     DOI: 10.1016/s0010-440x(99)90126-8

Source DB:  PubMed          Journal:  Compr Psychiatry        ISSN: 0010-440X            Impact factor:   3.735


  19 in total

1.  Obsessive-compulsive symptoms and cigarette smoking: an initial cross-sectional test of mechanisms of co-occurrence.

Authors:  Gregory S Chasson; Casey R Guillot; Michael J Zvolensky; Madalyn M Liautaud; Norman B Schmidt; Adam M Leventhal
Journal:  Cogn Behav Ther       Date:  2020-04-23

2.  The relationship between anxiety disorders and substance use among adolescents in the community: specificity and gender differences.

Authors:  Ping Wu; Renee D Goodwin; Cordelia Fuller; Xinhua Liu; Jonathan S Comer; Patricia Cohen; Christina W Hoven
Journal:  J Youth Adolesc       Date:  2009-01-13

3.  Cigarette smoking in obsessive-compulsive disorder and unaffected parents of OCD patients.

Authors:  Amitai Abramovitch; Diego A Pizzagalli; Daniel A Geller; Lillian Reuman; Sabine Wilhelm
Journal:  Eur Psychiatry       Date:  2014-03-14       Impact factor: 5.361

Review 4.  Co-morbidity of smoking in patients with psychiatric and substance use disorders.

Authors:  David Kalman; Sandra Baker Morissette; Tony P George
Journal:  Am J Addict       Date:  2005 Mar-Apr

Review 5.  Exploring Issues of Comorbid Conditions in People Who Smoke.

Authors:  Alana M Rojewski; Stephen Baldassarri; Nina A Cooperman; Ellen R Gritz; Frank T Leone; Megan E Piper; Benjamin A Toll; Graham W Warren
Journal:  Nicotine Tob Res       Date:  2016-01-17       Impact factor: 4.244

6.  The 5-year course of obsessive-compulsive symptoms and obsessive-compulsive disorder in first-episode schizophrenia and related disorders.

Authors:  Lieuwe de Haan; Bouke Sterk; Luuk Wouters; Don H Linszen
Journal:  Schizophr Bull       Date:  2011-07-28       Impact factor: 9.306

7.  Obsessive-compulsive symptoms and negative affect during tobacco withdrawal in a non-clinical sample of African American smokers.

Authors:  Mariel S Bello; Raina D Pang; Gregory S Chasson; Lara A Ray; Adam M Leventhal
Journal:  J Anxiety Disord       Date:  2016-10-05

Review 8.  Subtypes of nicotinic acetylcholine receptors in nicotine reward, dependence, and withdrawal: evidence from genetically modified mice.

Authors:  Christie D Fowler; Michael A Arends; Paul J Kenny
Journal:  Behav Pharmacol       Date:  2008-09       Impact factor: 2.293

9.  The role of the cholinergic system in the signal attenuation rat model of obsessive-compulsive disorder.

Authors:  Roni Yankelevitch-Yahav; Yankelevitch-Yahav Roni; Dapha Joel; Joel Daphna
Journal:  Psychopharmacology (Berl)       Date:  2013-05-18       Impact factor: 4.530

10.  An initial investigation of the relationships between hoarding and smoking.

Authors:  Amanda M Raines; Amanda S Unruh; Michael J Zvolensky; Norman B Schmidt
Journal:  Psychiatry Res       Date:  2014-01-10       Impact factor: 3.222

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.